Table 3.
Influence of inhibitory agents upon basal mRNA levels of nNOS, eNOS, iNOS and M2 mAChR
| Inhibitors | M2 (%) | nNOS (%) | eNOS (%) | N |
|---|---|---|---|---|
| None | 100 | 100 | 100 | 12 |
| AF-DX 116 | 98±7 | 93±8 | 93±9 | 5 |
| U-73122 | 110±9 | 91±7 | 108±7 | 5 |
| Trifluoperazine | 95±8 | 93±9 | 109±8 | 5 |
| Calphostin | 118±7 | 101±10 | 102±7 | 5 |
| L-NMMA | 96±8 | 104±9 | 88±6 | 5 |
| L-NIO | 97±8 | 95±6 | 102±9 | 5 |
| NZ | 112±9 | 97±7 | 108±7 | 5 |
Abbreviations: AF-DX 116, 11-((2-((diethylamino)methyl)-1-piperidinyl) acetyl)-5,11-dihydro-6H-pyrido (2,3-b)(1,4)benzodiazepin-6-one; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; L-NMMA, NG-monomethyl-L-arginine; L-NIO, N5-(1-iminoethyl)-L-ornithine dihydrochloride; M2 mAChR, M2 muscarinic acetylcholine receptor; nNOS, neuronal nitric oxide synthase; U-73122, 1-6-17β-3-methoxgestra-1,3,5 (10)-trien-17yl-aminohexyl-1-H-pyrrole-2,5-dione; NZ, N-propyl-L-arginine.
Results are mean±s.e.m. of N number of experiments and are expressed in percentage of variation from controls without drugs (none) taken as 100%.